门肺高压的管理与肝移植评估
门肺高压影响5%至6%的晚期肝病患者,占肺动脉高压病例的5%至15%,生存率显著低于特发性肺动脉高压。综述总结诊断与管理证据:肝移植候选者应行超声筛查,采用PAH药物治疗可改善肺血流动力学并助安全移植,肝移植可使半数患者门肺高压改善或缓解。
要点
- 所有肝移植候选者推荐超声心动图筛查门肺高压。
- 门肺高压采用与特发性肺动脉高压相似的PAH药物治疗。
- 肝移植可使半数患者门肺高压改善或缓解并改善生存。
核心结论
- 门肺高压预后差,受肺动脉高压和肝病严重程度双重影响。
- PAH药物联合肝移植在选定患者中与肺血流动力学和生存改善相关。
研究设计与样本
- 本文为已发表文献综述,总结门肺高压诊断与管理的证据和指南。
主要发现
- 门肺高压影响5%至6%的晚期肝病患者,占PAH病例的5%至15%。
- 与特发性PAH相比,门肺高压生存率显著更差。
- 肝移植围术期风险增加,可按平均肺动脉压和肺血管阻力分层。
- PAH治疗与肺血流动力学改善及安全肝移植相关。
- 肝移植可使半数患者门肺高压改善或缓解,并与高度选定患者生存改善相关。
关键数值与推荐
- 门肺高压定义为门静脉高压背景下存在毛细血管前肺动脉高压。
- 推荐所有肝移植候选者行超声心动图筛查以促进门肺高压检出和治疗。
临床怎么用
- 肝移植评估中应常规超声筛查门肺高压。
- 确诊后按特发性PAH模式给予PAH药物治疗以改善血流动力学。
- 经选择的患者可考虑肝移植,以期改善或缓解门肺高压。
局限性
- 原文指出PAH治疗门肺高压的证据匮乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Portopulmonary hypertension (POPH) affects 5% to 6% of patients with advanced liver disease and accounts for 5% to 15% of pulmonary arterial hypertension (PAH) cases. Compared with idiopathic PAH, POPH is associated with significantly worse survival. Recent studies have improved our understanding of the role of both PAH therapy and liver transplantation (LT) in the management of POPH and their impact on overall prognosis. We performed a review of the published literature to summarize the available evidence and guidelines regarding the diagnosis and management of POPH. POPH is defined by the presence of precapillary pulmonary hypertension in the context of portal hypertension. POPH is associated with increased perioperative risk at the time of LT, which can be stratified by mean pulmonary arterial pressure and pulmonary vascular resistance. Screening with echocardiography is recommended in all LT candidates to facilitate detection and treatment of POPH. Despite a paucity of evidence, POPH is treated similarly to idiopathic PAH with PAH therapy. These therapies are associated with improved pulmonary hemodynamics and facilitation of safe LT. LT can result in improvement or resolution of POPH in one-half of patients and has been associated with improved survival in highly selected patients. In summary, the prognosis in POPH is poor and is impacted by the severity of both pulmonary hypertension and liver disease. Management with a combination of PAH therapy and LT in selected patients has been associated with improved pulmonary hemodynamics and survival.
引用
- DuBrock HM. Portopulmonary Hypertension: Management and Liver Transplantation Evaluation. Chest. 2023. PMID: 36649754. doi:10.1016/j.chest.2023.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。